Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sitagliptin vs Glipizide in T2DM with Renal Insufficiency
NCT00509262Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2007
- Primary completion
- Mar 2011
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of sitagliptin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Merck & Co. Primary endpoints: Change From Baseline in Hemoglobin A1c at 54 weeks and Percentage of Participants With Hypoglycemic Events at 54 weeks. Started Oct 2007; status: completed.
02
Drugs
sitagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00509262.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00509262.